Zoetis Inc. (NYSE:ZTS) Expected to Announce Quarterly Sales of $1.98 Billion

Equities analysts expect Zoetis Inc. (NYSE:ZTSGet Rating) to announce sales of $1.98 billion for the current fiscal quarter, according to Zacks. Six analysts have provided estimates for Zoetis’ earnings. The highest sales estimate is $2.02 billion and the lowest is $1.92 billion. Zoetis posted sales of $1.87 billion in the same quarter last year, which would indicate a positive year-over-year growth rate of 5.9%. The company is scheduled to issue its next earnings results before the market opens on Monday, January 1st.

On average, analysts expect that Zoetis will report full-year sales of $8.45 billion for the current financial year, with estimates ranging from $8.40 billion to $8.48 billion. For the next fiscal year, analysts expect that the business will post sales of $9.19 billion, with estimates ranging from $8.99 billion to $9.36 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow Zoetis.

Zoetis (NYSE:ZTSGet Rating) last announced its earnings results on Tuesday, February 15th. The company reported $1.00 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.96 by $0.04. The business had revenue of $1.97 billion during the quarter, compared to analyst estimates of $1.93 billion. Zoetis had a return on equity of 50.71% and a net margin of 26.20%. Zoetis’s revenue for the quarter was up 8.9% compared to the same quarter last year. During the same period last year, the company earned $0.91 EPS.

ZTS has been the subject of a number of analyst reports. Citigroup cut their price target on Zoetis from $232.00 to $208.00 and set a “neutral” rating for the company in a research note on Wednesday, March 9th. Zacks Investment Research downgraded Zoetis from a “buy” rating to a “hold” rating and set a $242.00 target price on the stock. in a research note on Saturday, January 8th. Finally, StockNews.com cut shares of Zoetis from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 5th. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $224.78.

ZTS stock opened at $187.91 on Wednesday. The company has a current ratio of 3.86, a quick ratio of 2.79 and a debt-to-equity ratio of 1.45. The stock has a 50-day moving average price of $193.03 and a 200-day moving average price of $207.34. The firm has a market cap of $88.66 billion, a PE ratio of 44.01, a price-to-earnings-growth ratio of 3.39 and a beta of 0.77. Zoetis has a 1-year low of $161.49 and a 1-year high of $249.27.

The company also recently declared a quarterly dividend, which will be paid on Wednesday, June 1st. Stockholders of record on Thursday, April 21st will be issued a dividend of $0.325 per share. This represents a $1.30 dividend on an annualized basis and a dividend yield of 0.69%. The ex-dividend date of this dividend is Wednesday, April 20th. Zoetis’s payout ratio is 30.45%.

In other Zoetis news, EVP Glenn David sold 32,390 shares of Zoetis stock in a transaction on Wednesday, February 23rd. The shares were sold at an average price of $189.87, for a total value of $6,149,889.30. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Roxanne Lagano sold 2,065 shares of Zoetis stock in a transaction on Tuesday, February 15th. The shares were sold at an average price of $196.54, for a total transaction of $405,855.10. The disclosure for this sale can be found here. Insiders sold 50,455 shares of company stock worth $9,607,544 in the last 90 days. 0.21% of the stock is currently owned by corporate insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Investment Research & Advisory Group Inc. purchased a new position in shares of Zoetis during the 4th quarter worth about $26,000. Account Management LLC bought a new stake in shares of Zoetis in the 4th quarter valued at about $2,715,000. Financial Management Professionals Inc. bought a new stake in shares of Zoetis in the 3rd quarter valued at about $25,000. Amplius Wealth Advisors LLC bought a new stake in shares of Zoetis in the 4th quarter valued at about $31,000. Finally, Aquire Wealth Advisors LLC bought a new stake in shares of Zoetis in the 4th quarter valued at about $32,000. Institutional investors own 90.36% of the company’s stock.

About Zoetis (Get Rating)

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Read More

Get a free copy of the Zacks research report on Zoetis (ZTS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.